STAT Plus: Genentech, a biotech with a storied past, confronts new turbulence in the present
Genentech
Genentech, the U.S. arm of drug giant Roche, offered
the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Two of its well-known anti-cancer drugs are Herceptin and Avastin.
Latest
STAT Plus: From drug shortages to high prices, U.S. system’s shortcomings have deep roots
STAT Plus: EPA fines Roche’s Genentech unit for hazardous waste violations
STAT Plus: Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
Doctors use precision medicine to show melanoma drugs can shrink rare brain tumor by 90%
STAT Plus: Roche shortens delivery time for multiple sclerosis drug from hours to minutes in trial
STAT Plus: Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case
